Skip to main content Skip to main navigation menu Skip to site footer

Transarterial Chemoembolization in Hepatocellular Carcinoma: A Clinical Efficacy Study of Ganoderma Lucidum Extract Polysaccharide Peptide β-Glucan


Background: Hepatocellular carcinoma (HCC) is a primary liver malignancy with high prevalence rate, associated primarily with the Hepatitis B Virus. HCC is the third leading cause of death worldwide. The prevalence in Indonesia is estimated at 100 per100,000 inhabitants. Treatment is generally ineffective as patients are already at advanced stages when diagnosed. Trans-arterial Chemoembolization (TACE) is a promising treatment, and β-Glucan combined therapy is expected to treat HCC more efficiently. This study evaluated the treatment response of TACE in HCC combined with β-Glucan orally.

Methods: A randomized clinical trial was conducted on 63 patients with HCC. The subjects of the study were randomly assigned into two groups: 32 administered TACE plus β-Glucan, and 31 with TACE plus placebo.

Results: In the β-Glucan group, there were four patients (12.50%) with complete response, 16 (50%) partial response, 3 (9.38%) no response, and 9 (28.12%) in deteriorated response. In the placebo group, there were 0 complete response, 11(35.48%) partial, 2(6.45%) no response, and 18 (58.07%) deteriorated response. The survival rate of the β-Glucan group was longer (median 39 weeks) than the placebo group (median 26 weeks). CD4, CD8 and IL-2 post-TACE increased significantly (p<0.05). The placebo group had 4.143 times, significantly higher hazard risk (p<0.05).

Conclusion: HCC therapy with a combination of TACE and β-Glucan is beneficial to increase the therapeutic response, immunity and survival rate.


  1. World Health Organization. Mortality Database. Available from: GAR Hepatitis.2002. (accessed: 13 February 2012)
  2. Behboudi S, Pereira SP. Alpha-fetoprotein specific CD4 and CD8 T cell responses in patients with hepatocellular carcinoma. World J Hepatol. 2010; 2(7):256-260.
  3. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005; 55:74–108.
  4. Montalto G, Cervello M, Giannitrapani L, Dantona F, Terranova A, Castagnetta LA. Epidemiology, risk factors, and natural history of hepatocellular carcinoma. Ann N Y Acad Sci. 2002; 963:13-20.
  5. Badan Penelitian dan Pengembangan Kesehatan Departemen Kesehatan RI. Laporan Nasional Riset Kesehatan Dasar (RISKESDAS) 2007. 2008. Available from:
  6. YKI. YKI-Jakarta Race, September,12. 2012.
  7. Kao JH, Chen DS. Changing disease burden of hepatocellular carcinoma in the Far East and Southeast Asia. Liver Diseases. 2005;5(2):479-507.
  8. Nguyen, V.T., Law, M.G., Dore, G.J. (2009) Hepatitis-B related hepatocellular carcinoma: epidemiological characteristics and disease burden. J Viral Hepat. 2009; 16(7): 453-463.
  9. Colombo M. Malignant neoplasm of the liver. In: Schiff ER, Sorrel MF, Maddrey WC, editors. Schiff’s Diseases of the Liver, 9th ed, volume 2. Philadelphia: Lippincort Williams & Wilkins; 2003. p. 1377-1403.
  10. Block TM, Mehta AS, Fimmel CL. Molecular viral oncology of hepatocellular carcinoma. Oncogene. 2003; 22(33): 5093-5107.
  11. Anthony PP. Hepatocellular carcinoma: An overview. Histopathology. 2001; 39(2):109-118.
  12. Venook AP, Papandreou C, Furuse J, de Guevara LL. The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective. The Oncologist. 2010; 15(suppl 4): 5-13.
  13. Yaqi Z, Minshan C. Karsinoma Hati Primer. In: Buku Ajar Onkologi Klinis. Edisi 2. Editor Utama: Desen W. Translator: Japaries W. Jakarta: FKUI; 2008. p. 408-423.
  14. Yeung YP, Lo CM, Liu CL. Natural history of untreated nonsurgical hepatocellular carcinoma. Am J Gastroenterol. 2005; 100(9):1995-2004.
  15. Hennedige T, Venkatesh SK. Imaging of hepatocellular carcinoma: diagnosis, staging, and treatment monitoring. Cancer Imaging. 2012; 12(3): 530-547.
  16. Ursino S, Greco C, Cartei F, Colosimo C, Stefanelli A, Cacopardo B, Berretta M, Fiorica F. Radiotherapy and hepatocellular carcinoma: update and review of the literature. Eur Rev Med Pharmacol Sci. 2012; 16:1599-1604.
  17. Tatli S, Tapan U, Morrison PR, Silverman SG. Radiofrequency ablation: technique and clinical applications. Diagn Interv Radiol. 2012; 18: 508-516.
  18. Chan GC, Chan WK, Sze DM. The effect of β-Glucan on human immune and cancer cells. J Hematol Oncol. 2009; 2(25): 1-11.
  19. Zhou S, Gao Y. The immunomodulating effect of Ganoderma lucidum (Curt.: Fr.) P. Karst. (Ling Zhi, Reishi Mushroom) (Aphyllophoromycetidese). International Journal of Medical Mushrooms. 2002; 4:1-11.
  20. Cao QZ, Lin ZB. Antitumor and antiangiogenic activity of Ganoderma lucidum polysaccharides peptide. Acta Pharmacogical Sinica. 2004; 25(6):833-838.
  21. Mason R. What is Beta-Glucan? A Concise Guide to the Benefits and Uses of the Most Powerful Natural Immune Enhancer Known to Science. Printed in the USA. Fall 2011 Revision. 561 Shunpike Road Sheffield, MA 01257. 2001; 6-9.

How to Cite

Poedjomartono, B., Faisal, A., & Nurjanah, S. (2020). Transarterial Chemoembolization in Hepatocellular Carcinoma: A Clinical Efficacy Study of Ganoderma Lucidum Extract Polysaccharide Peptide β-Glucan. Bali Medical Journal, 9(1), 31–35.




Search Panel